Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Scientists uncover new obesity genes that reshape understanding of weight and disease risk

A global research team maps how rare and common gene variants jointly drive obesity and metabolic disease, offering fresh clues for equitable, personalized prevention and treatment. Study: Discovery of obesity genes through cross-ancestry analysis. Image Credi

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

A global research team maps how rare and common gene variants jointly drive obesity and metabolic disease, offering fresh clues for equitable, personalized prevention and treatment.

Study: Discovery of obesity genes through cross-ancestry analysis. Image Credit: jittawit21 / Shutterstock

In a recent study published in the journal Nature Communications, a group of researchers identified and validated genes associated with Body Mass Index (BMI) across multiple ancestries using rare protein-truncating variants (PTVs), and mapped their relationships with comorbidities, plasma proteins, and polygenic risk.

Global Obesity Trends and Genetic Gaps

One in eight adults worldwide now lives with obesity, and small changes on the scale can ripple into diabetes, heart failure, and joint disease at home and in clinics. Why some people gain weight more easily remains partly genetic, yet most discoveries have come from European-only cohorts that do not reflect global diversity. BMI simplifies weight into a number, but the biology spans brain appetite circuits, adipose tissue, hormones, and the environment. Understanding rare, high-impact variants alongside the common polygenic burden can refine prevention and treatment strategies. Further research should move beyond single-ancestry designs to ensure genetic findings translate equitably.

Cross-Ancestry Study Design and Data Sources

The investigators analyzed 839,110 adults from the United Kingdom Biobank (UKB) and All of Us (AoU) spanning six continental ancestries. They performed ancestry inference using principal components and random forests, then ran gene-based rare-variant association tests with REGENIE v3.317, collapsing PTVs and deleterious missense variants into masks per gene. BMI was inverse-normal transformed within ancestry and sex strata. Covariates included age, age-squared, sex, age by sex, exome release batch (rather than genotyping batch), and the first ten genetic principal components. Results were meta-analyzed with inverse-variance-weighted fixed effects to create European, non-European, and all-ancestry summaries, with heterogeneity assessed by Cochran’s Q.

Statistical Analyses and Sensitivity Testing

Sensitivity checks included leave-one-variant-out analyses and conditioning on nearby common-variant signals. Phenome-wide association study (PheWAS) models tested clinical diagnoses. Structural equation modeling (SEM) was used to evaluate whether BMI mediated gene-comorbidity paths. Polygenic scores (PGS) for BMI quantified common-variant burden and its interaction with rare variants. Plasma proteomics in approximately 50,000 UKB participants linked PTV-carrier status to circulating proteins. The functional context was drawn from the Genotype-Tissue Expression project (GTEx), the International Mouse Phenotyping Consortium (IMPC), and the Common Metabolic Diseases Knowledge Portal (CMDKP).

Discovery of Novel BMI-Associated Genes

Thirteen genes reached exome-wide significance for association with BMI, including established loci such as melanocortin 4 receptor (MC4R), bassoon presynaptic cytomatrix protein (BSN), and proprotein convertase subtilisin/kexin type 1 (PCSK1), and five previously unreported associations: replication timing regulatory factor 1 (RIF1), YLP motif containing 1 (YLPM1), GRB10 interacting GYF protein 1 (GIGYF1), solute carrier family 5 member 3 (SLC5A3), and glutamate metabotropic receptor 7 (GRM7). After controlling for genomic inflation, associations for SLC5A3 and GRM7 were at suggestive significance, with effect sizes consistent with those observed in the primary analysis. Effect sizes for several of these rare protein-truncating variant burdens were comparable to those of canonical obesity genes, with YLPM1 and RIF1 showing magnitudes similar to those of MC4R and BSN. YLPM1, MC4R, and SAFB-like transcription modulator (SLTM) showed consistent effects in European and non-European groups, indicating broad generalizability. No gene reached exome-wide significance within any single non-European ancestry stratum, underscoring limited power for ancestry-specific discovery. In contrast, GRM7 showed significant heterogeneity by ancestry, and APBA1 displayed a European-biased effect, highlighting how ancestry composition can shape discovery and therapeutic targeting.

Gene-Carried Risks for Obesity and Comorbidities

Clinically, carriers of PTVs in YLPM1, RIF1, GIGYF1, and GRM7 had higher odds of being in the obesity and severe obesity categories, whereas SLC5A3 did not show enrichment for these categories. Beyond weight, cardiometabolic comorbidity patterns emerged. For example, BSN and GIGYF1 carriers exhibited elevated risk for type 2 diabetes, with BSN carriers also showing higher risk of hypertension and heart failure. SEM indicated that the risk of type 2 diabetes in BSN, GIGYF1, and SLTM carriers reflected both a direct pathway from gene to disease and an indirect pathway mediated by BMI. Conversely, the risk of gastroesophageal reflux disease (GERD) in SLC5A3 carriers appeared to be independent of BMI, suggesting that SLC5A3 increases GERD risk via a BMI-independent path and distinct mechanisms for the symptom clusters that patients experience.

Pleiotropy and Functional Validation Across Systems

A PheWAS expanded the view of pleiotropy. YLPM1 carrier status is associated with altered mental status and cholelithiasis, while GIGYF1 is associated with hypothyroidism and chronic renal failure alongside type 2 diabetes. Expression and model-organism data placed most of the implicated genes in brain regions and adipose tissue, consistent with central nervous system regulation of appetite, energy balance, and downstream adiposity. Heterozygous knockout of Ylpm1 in mice increased body fat mass and fasting glucose, supporting a causal role.

Combined Effects of Rare Variants and Polygenic Risk

PGS analyses showed additive effects between common-variant burden and rare high-impact variants. Among carriers, obesity prevalence rose steadily from the lowest to highest PGS quintiles in both UKB and AoU, and mean BMI was substantially higher in carriers with high polygenic load. This pattern suggests that everyday risk accrues from many small variants even when a single rare variant is present.

Plasma Protein Pathways Linked to Obesity Genes

Plasma proteomics identified rare variants associated with circulating proteins linked to metabolic health. SLTM carrier status is associated with higher leukocyte cell-derived chemotaxin 2 (LECT2), a hepatokine that tracked positively with BMI in the broader cohort. GIGYF1 carriers had lower odontogenic ameloblast-associated protein (ODAM) and neurocan (NCAN), and bridge-like lipid transfer protein family member 1 (BLTP1) carriers had higher cluster of differentiation 164 (CD164) and tumor necrosis factor superfamily member 12 (TNFSF12), with all of these protein levels also related to BMI. These relationships nominate downstream protein pathways that could be monitored or targeted.

Implications for Global Obesity Research

Across six ancestries and two large biobanks, the study identified five previously unreported obesity-associated genes and clarified which signals are generalizable across populations. The findings connect rare PTVs, common polygenic background, and plasma proteins to real-world outcomes such as type 2 diabetes, hypertension, heart failure, and gastroesophageal reflux disease. For families and clinicians, this means risk is not destiny but a layered combination of high-impact and polygenic influences. For researchers and developers, cross-ancestry sampling is crucial to avoid biased targets and promote equity.

  • Banerjee, D. & Girirajan, S. (2025). Discovery of obesity genes through cross-ancestry analysis. Nature Communications, 16. DOI: 10.1038/s41467-025-64933-7 https://www.nature.com/articles/s41467-025-64933-7

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Why are these clinical trial results so groundbreaking?

There are no targeted treatments approved for pancreas cancer, and we haven't had any significant progress for a long time. We've only come up with different chemotherapy combinations, and those are only moderately effective. This new treatment is staggeringly better than chemotherapy. Usually, when we think of an improvement in pancreatic cancer survival, we think of 25% improvement. This medication actually doubled survival in patients with advanced disease. We have patients who participated in the trial who are still alive, which is unheard of because the five-year survival rate for pancreatic cancer patients is only 13%-14%. If the drug is approved by the FDA, it will most likely become the new standard of care for advanced pancreatic cancer and could replace chemotherapy as a first-line treatment.

Source: www.news-medical.net ↗
02In safety assessment, the consequences of being wrong are significant. How do you think about uncertainty and model limitations for safety and discovery?

Uncertainty and model limitations are critical in safety assessment. There is clearly greater potential for animal or human harm from an incorrect safety assessment than from making the wrong molecule in early discovery, although uncertainty matters in both contexts. It is important to distinguish different types of uncertainty. Aleatoric uncertainty reflects irreducible randomness in a task, while epistemic uncertainty is model-related, such as hallucinations or lack of knowledge. For LLM systems, we use multiple methods to measure consistency and we have built fact-checking approaches in which a separate LLM independently verifies the primary engine's outputs. For QSAR models, including our SAR work around seizure liability, we can use statistical metrics such as confidence intervals to quantify and communicate uncertainty. Understanding that uncertainty exists and communicating it in both safety and discovery is critical. Uncertainty metrics tell us where potential blind spots may exist in our modelling allowing us to take action to improve over time. This applies to both safety and discovery. The aim is not to pretend AI removes uncertainty, but to make uncertainty visible so scientists can make better-informed decisions. Download the Full PDF to Revisit James McDonagh's Insights on AI in Drug Safety Discovery

Source: www.news-medical.net ↗
03What impact do you think the use of AI in drug discovery could ultimately have for patients?

One of the first ways in which this would be really felt by patients is through the repurposing of existing drugs for new diseases. Clearly, even though one could improve the process in a number of ways in terms of speeding up medicinal chemistry programs and potentially speeding up the amount of things such as toxicity trials etc., that is still going to take time. However, if we can take existing drugs, perhaps drugs which have gone off patent or are currently being marketed for another indication, and repurpose them in areas where there are high unmet medical needs, those drugs could go into that new indication in phase 2 in patients and you would know very quickly whether the drug worked or not. Then the route to market or the route to being able to make the drug more broadly available to patients would be much more rapid because you don't have to go through all those earlier stages of toxicity, testing, phase 1 testing, volunteers and so on.

Source: www.news-medical.net ↗
04What are carbs?

Your weight loss plan should keep you healthy and strong as you lose the extra weight. Many plans include a diet low in carbohydrates. Carb cycling is a method of optimizing your carbohydrate intake to meet your needs while dieting, fasting, and working out. When you're carb cycling, you consume carbs to meet your needs on some days and avoid them on other days. The aim of carb cycling is to consume carbohydrates when your body needs them and exclude them at other times. Such strategies in your diet plan can help your weight loss efforts. Carbohydrates, or carbs, are a significant part of the average human diet. Along with proteins and fats, they make up the bulk of your daily meals. Most carbohydrates are broken down by your body into glucose to provide energy for your cells and tissues. Carbohydrates in your diet are of three types — sugars, starches, and fiber. Sugars are simple carbs. Glucose, sugar (sucrose), lactose found in milk, and fructose found in fruits, are naturally occurring sugars. Your body metabolizes these molecules rapidly to yield energy. Starches are complex carbs. They're large molecules that consist of hundreds of molecules of simple sugars joined together. Your body needs to break them down to release energy. Starches are found in bread, potatoes, peas, corn, cereals, and pasta. Fiber is also a complex carbohydrate. Human bodies can't break down these large molecules, so they provide no energy. They're usually excreted as they are in the feces. They add bulk to your meal, so you feel full. Fiber in the diet helps avoid constipation and lowers blood sugar and cholesterol levels. Carbohydrates are an essential part of your diet. A typical diet provides 45% to 65% of its calories from carbohydrates. If you have 2,000 calories a day, you should have about 275 grams of carbohydrates. Always try to choose healthy foods for your carb intake:

Source: www.medicinenet.com ↗
05Are supplements necessary?

Daily, if you eat a balanced diet that includes healthy foods, you technically should not need a vitamin supplement. A healthy diet incorporates lean proteins, healthy fats, grains, fruits, and vegetables. But if you do not have a balanced diet, you may be considering hair, skin, and nail vitamins. Some people prefer supplements, sometimes choosing a multivitamin that can supply all of your essential minerals and vitamins. But taking too much of vitamins or unnecessary supplements is wasteful because the body gets rid of excess vitamins and minerals or, worse, it can be dangerous. The following is a guide to choosing which vitamins you may want to consider supplementing and when. Deficiencies in the nutrients that keep the skin, hair, and nails healthy can cause changes over time. For example, not enough intake of vitamins A and E, along with not enough biotin, can cause scaly and rough skin patches, eczema, and hair loss. If there is a deficiency, vitamins will help. However, if there is no deficiency, there is no clear evidence that supplements will make a difference. No research studies concluded that supplements treat or prevent age-related, natural hair damage or loss or lead to healthier skin. Two studies in the early 1990s did suggest that a biotin supplement may cause the hair to become stronger and strengthen weak nails. However, the studies were small and not reproduced.

Source: www.medicinenet.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides

01
Peptide Therapy Guide Editorial Team

What is Protein A?

Protein A is a 42KDa cell surface protein which is found on the cell walls of 90% of Staphylococcus aureus bacterial strains. It is encoded for by the polymorphic X-region of the SpA gene, and functions as an …

Read guide →